How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week
Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome treatment.
Advertisement
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome treatment.